Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Optimal Combination Therapy After Nevirapine Exposure

Trial Profile

Optimal Combination Therapy After Nevirapine Exposure

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OCTANE; OCTANE-1
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Mar 2018 Results assessing association between virological failure of ART and HIV variant with dual-class resistance by using data from this study presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5175 trial, were presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top